Sonoma Pharmaceuticals, Inc. (SNOA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on December 15, 2023. The filing discloses the entry into a material definitive agreement regarding the potential sale of the company's common stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new equity distribution agreement.
Material Changes and Agreements
On December 15, 2023, the Company entered into an Equity Distribution Agreement with Maxim Group LLC ("Maxim"). Key terms include:
- Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $392,077.
- Sales Method: Sales may be conducted as "at the market" offerings or other permitted methods, subject to the Company's instructions on price, time, and size.
- Compensation: Maxim will receive a commission of 3% of the aggregate gross proceeds from each sale.
- Expenses: The Company agreed to reimburse Maxim for specified expenses up to $20,000.
- Obligation: The Company is not obligated to sell any shares, and no assurance is given regarding the price, amount, or timing of any sales.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the Company's intentions and expectations. It explicitly states that actual outcomes may differ materially due to risks and uncertainties. The agreement terminates upon the sale of all shares or as otherwise provided in the agreement. No specific operational guidance or outlook was provided in this report.
Investor Verification Checklist
- Verify the current share price and market capitalization to assess the potential dilution impact of the $392,077 offering capacity.
- Review the Company's most recent Form 10-K or 10-Q for actual liquidity and cash position, as this 8-K does not provide financial statements.
- Monitor future filings to determine if and when the Company elects to sell shares under this agreement.
- Confirm the status of the Form S-3 registration statement (File No. 333-275311) referenced in the filing.